2020 American Transplant Congress
The Impact of DSA Screening in Stable Kidney Transplant Recipients in the 1st Year Post-Transplant
*Purpose: The importance of Donor Specific Antibody (DSA) as a screening tool within the 1st year post kidney transplant in stable patients remains unclear. We…2020 American Transplant Congress
The Role of Galectin-1 and Basement Membrane Remodeling in Kidney Antibody-Mediated Rejection
*Purpose: Antibody-mediated rejection (AMR), the leading cause of kidney graft loss, is caused by anti-HLA and non-HLA antibodies against proteins in two main kidney compartments:…2020 American Transplant Congress
The Ratio between Naïve and Memory B Cells is Associated with Development of Early Donor-Specific Antibodies within the First Month after Lung Transplantation
*Purpose: After lung transplantation (LuTx), the development of early donor HLA-specific antibodies (eDSA) has been shown to be associated with antibody-mediated rejection (AMR) and poor…2020 American Transplant Congress
CD56DimCD16Bright NK Cells from Kidney Transplant Recipients with Antibody-Mediated Rejection Display Increased Proliferation, Self-Renewal, Pro-Inflammatory and Cytotoxic Profile
*Purpose: Contribution of NK cells to antibody-mediated rejection (ABMR) injuries have recently been highlighted through transcriptomic analysis and immunohistochemistry of kidney and heart allograft biopsies.…2020 American Transplant Congress
Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients
Stanford University School of Medicine, Stanford, CA
*Purpose: Hypersensitized kidney transplant recipients (calculated panel reactive antibody (cPRA) ≥98%) may represent a population at high risk of posttransplant immunologic events. While access to…2020 American Transplant Congress
Follow Up of Imlifidase (IdeS) Desensitized Kidney Transplant Recipients
*Purpose: 46 highly sensitized patients received kidney transplants after desensitization with imlifidase (currently under investigation) across four Phase 2 clinical trials, and 6-month safety and…2020 American Transplant Congress
Development and Impact of DSA after Lung Transplant
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is a serious complication, potentially leading to graft failure despite advances in drug therapy. Diagnosis and treatment…2020 American Transplant Congress
The Liver Protects All? Donor Specific Antibody Formation in Heart-Liver Transplant Recipients
*Purpose: Donor specific antibodies (DSAs) are key in the development of antibody mediated rejection (AMR). Their role in decreased patient and graft survival has been…2020 American Transplant Congress
Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody
*Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 47
- Next Page »